维多利亚，塞舌尔, June 16, 2025 (GLOBE NEWSWIRE) -- 领先的加密货币交易所和 Web3 公司 Bitget 宣布为其 Onchain 平台推出一系列重大功能升级，包括限价订单、智能仓位止盈止损和新代币提醒功能，旨在为用户提供更高的精准度、更强的掌控力以及链上交易的实时洞察。 最新升级在交易执行、风险管理、市场追踪和用户体验等领域实现了显著优化。 限价订单功能现已上线，助力交易者以更高的精准度和效率自定义执行价格。 Onchain 平台还支持智能止盈止损工具，使用户能够预设目标利润或亏损，一键即可实现仓位自动管理。 为给予交易者更大灵活性，现在可在多种模式下调整燃料费和滑点设置。 Bitget Onchain 还改进了实时市场可视化。 K 线蜡烛图现已实现实时更新，确保用户在价格变动时能获取最新市场数据。 新的图表叠加功能将价格数据与市值相结合，提供双重视角以支持更明智的决策。 该平台还推出了新的代币订阅功能，在新代币上线时发送即时提醒，帮助用户把握新兴机会。 搜索功能也已升级，支持使用合约地址直接查询，更易识别高潜力资产。 此外，Bitget Onchain 推出了新的分享 ...

Core Insights - Intellia Therapeutics announced promising three-year follow-up data from the Phase 1 portion of its ongoing Phase 1/2 study for lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) [1][2] - All 10 patients in the Phase 1 study were attack-free and treatment-free for a median of nearly two years, demonstrating the potential of lonvo-z as a one-time therapy [2][6] - The global Phase 3 HAELO trial has completed screening ahead of schedule, with over half of the patients screened in the United States [4][6] Clinical Results - A single dose of lonvo-z led to a mean reduction in monthly HAE attack rate of 98% compared to pre-treatment baseline [2][6] - Patients showed deep, dose-dependent, and durable reductions in plasma kallikrein protein levels throughout the study [2][6] - The treatment was well tolerated, with the most frequent adverse events being infusion-related reactions, which were mostly Grade 1 and resolved without complications [3][6] Development Plans - The ongoing Phase 3 HAELO trial is randomized, double-blind, and placebo-controlled, assessing the safety and efficacy of lonvo-z at the 50 mg dosage [4][5] - Intellia plans to submit a biologics license application (BLA) in 2026, aiming for a U.S. launch in 2027 [4][8] - New data from the Phase 2 portion of the ongoing Phase 1/2 study is expected to be presented in the second half of 2025 [4][10] About Lonvo-z - Lonvo-z is based on CRISPR/Cas9 technology and aims to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene [8] - The therapy has received multiple regulatory designations, including Orphan Drug and RMAT Designation from the FDA [8][9] - Intellia is focused on leveraging gene editing technology to develop novel therapies that address unmet medical needs [9]

自今年年初以来，Agent 赛道的热度持续了好几个月。有非常多各种方向和概念的 Agent 项目已经拿到融 资，而很多人也已经开始思考： 下一波机会，会出现在哪里？ 活动中，我们会展开讲讲从「给人做产品」到「给 Agent 做产品」的演化路线、Agent Infra 有哪些值得重写 一遍的机会、为什么 Agent 需要自己的 browser、做 browser use 的实践和方法论，以及 Agent 长期记忆问题 的解决方案和进展等话题。 具体报名信息请见下方海报。为保证小型、私密的活动交流氛围，本次活动限 50 人（非投资行业），我们 会优先通过回答更认真、跟我们背景更匹配的朋友，具体通过情况请以工作人员通知为准。 期待和大家见面！ 所以下周六（6/21）下午，我们会在北京组织一场线下活动，邀请到包括雷磊在内的两位长期在第一线实践 的创业者朋友，带来他们对 Agent Infra 的深入观察和方法论。 我们看到的新机会之一，就是 Agent Infra。 这次我们请来了 Grasp（一款给 Agent 用的浏览器） 创始人雷磊，请他在播客中分享了很多有关 Agent Infra 的观察与思考，比如为什么 ...

具体报名信息请见下方海报。为保证小型、私密的活动交流氛围，本次活动限 50 人（非投资行业），我们 会优先通过回答更认真、跟我们背景更匹配的朋友，具体通过情况请以工作人员通知为准。 期待和大家见面！ 不过雷磊对于「给 Agent 做产品」这件事，还有很多播客节目中承载不下的观察和思考。 所以下周六（6/21）下午，我们会在北京组织一场线下活动，邀请到包括雷磊在内的两位长期在第一线实践 的创业者朋友，带来他们对 Agent Infra 的深入观察和方法论。 活动中，我们会展开讲讲从「给人做产品」到「给 Agent 做产品」的演化路线、Agent Infra 有哪些值得重写 一遍的机会、为什么 Agent 需要自己的 browser、做 browser use 的实践和方法论，以及 Agent 长期记忆问题 的解决方案和进展等话题。 自今年年初以来，Agent 赛道的热度持续了好几个月。有非常多各种方向和概念的 Agent 项目已经拿到融 资，而很多人也已经开始思考： 下一波机会，会出现在哪里？ 我们看到的新机会之一，就是 Agent Infra。 这次我们请来了 Grasp（一款给 Agent 用的浏览器） 创 ...

Griffin团队 投稿 量子位 | 公众号 QbitAI 在企业系统和科学研究中普遍存在、结构复杂的关系型数据库（Relational DataBase, RDB）场景中，基础模型的探索仍处于早期阶段。 这是因为RDB中的多表交互和异质特征，使传统通用大模型在此类结构化环境下难以直接发挥效能。 基于此，北京大学 张牧涵团队 联合亚马逊云科技共同提出了 Griffin ：一个具有开创性的、以图为中心的RDB基础模型。 Griffin将RDB视为动态异质图进行建模与推理，通过在超过1.5亿行的表格数据上进行预训练和监督微调，构建了一个具备可迁移性与强泛化 能力的基础模型，相关成果已被国际顶级会议ICML 2025正式接收。 挑战：复杂的表间关系及丰富的表内语义信息 关系数据库通过明确的模式（Schema）定义数据结构，广泛服务于金融、电商、科研、物流、政府信息系统等关键领域，是现代信息社会的 核心数字基础设施。 根据市场预测，到2028年全球数据库管理系统（DBMS）市场将超过1330亿美元。 然而，RDB智能建模所面临的挑战极为复杂，集中体现在以下三方面： 拓扑结构高度复杂 数据以多表形式存储，并通过主键外键 ...

Griffin团队 投稿 量子位 | 公众号 QbitAI Griffin将RDB视为动态异质图进行建模与推理，通过在超过1.5亿行的表格数据上进行预训练和监督微调，构建了一个具备可迁移性与强泛化 能力的基础模型，相关成果已被国际顶级会议ICML 2025正式接收。 挑战：复杂的表间关系及丰富的表内语义信息 关系数据库通过明确的模式（Schema）定义数据结构，广泛服务于金融、电商、科研、物流、政府信息系统等关键领域，是现代信息社会的 核心数字基础设施。 根据市场预测，到2028年全球数据库管理系统（DBMS）市场将超过1330亿美元。 在企业系统和科学研究中普遍存在、结构复杂的关系型数据库（Relational DataBase, RDB）场景中，基础模型的探索仍处于早期阶段。 这是因为RDB中的多表交互和异质特征，使传统通用大模型在此类结构化环境下难以直接发挥效能。 基于此，北京大学 张牧涵团队 联合亚马逊云科技共同提出了 Griffin ：一个具有开创性的、以图为中心的RDB基础模型。 然而，RDB智能建模所面临的挑战极为复杂，集中体现在以下三方面： 拓扑结构高度复杂 数据以多表形式存储，并通过主键外键 ...

Summary of Beam Therapeutics Conference Call Company Overview - **Company**: Beam Therapeutics (BEAM) - **Industry**: Gene Editing and Gene Therapy, specifically targeting sickle cell disease Key Points and Arguments 1. **Vision and Mission**: Beam aims to provide lifelong cures for patients with serious diseases through one-time curative therapies, particularly for sickle cell disease [5][12][46] 2. **Clinical Trial Update**: The BEACON trial for BEAM-101 in sickle cell disease has shown promising results, with the potential to be a best-in-class option for patients [5][10][12] 3. **Patient Story**: A patient named Brandon, who suffered from severe sickle cell disease, received BEAM-101 and has since experienced significant improvements in health and quality of life [6][7] 4. **Financial Position**: Beam has a strong balance sheet with $1.2 billion in cash and equivalents, expected to support operations until 2028 [7] 5. **Clinical Proof of Concept**: Beam has established clinical proof of concept for its base editing technology and delivery methods, with strong evidence of efficacy and safety [8][9] 6. **Regulatory Progress**: Beam has received IND clearance and orphan drug designations from the FDA for its lead programs, including BEAM-302 for alpha-one antitrypsin deficiency [10][45] 7. **Market Potential**: The peak annual revenue potential for the sickle cell market is estimated to be between $3 billion to $4 billion, with a strong reimbursement landscape [14][15] 8. **Patient Demand**: There is significant demand for BEAM-101, with many patients on waiting lists for treatment, indicating that demand is outpacing supply [16][17][92] 9. **Manufacturing Efficiency**: Beam's internal GMP manufacturing allows for high yields and rapid processing, contributing to a more efficient treatment process [20][42][44] 10. **Safety and Efficacy**: The BEACON trial has shown rapid engraftment of edited cells, with median times of 16.5 days for neutrophil engraftment and 19.5 days for platelet engraftment [27][42] 11. **Clinical Outcomes**: All patients treated with BEAM-101 have achieved hemoglobin F levels above 60% and hemoglobin S levels below 40%, indicating a successful treatment response [19][30][39] 12. **Quality of Life Improvements**: Patients have reported significant improvements in quality of life, including the ability to engage in activities previously restricted due to their condition [78][79] Additional Important Content - **Wave Strategy**: Beam's approach includes multiple waves of treatment, with Wave 1 focusing on BEAM-101, Wave 2 incorporating non-genotoxic conditioning, and Wave 3 exploring in vivo delivery methods [13][14] - **Patient Experience Metrics**: Metrics such as mobilization, hospital stay, safety, and efficacy will influence provider capacity and therapy choice [15] - **Regulatory Environment**: The reimbursement landscape is evolving, with improvements expected as more standardized plans are adopted [56][58] - **Future Outlook**: Beam is optimistic about the commercial outlook for its therapies and plans to advance its next-generation innovations in hematology [45][46] This summary encapsulates the key points discussed during the conference call, highlighting Beam Therapeutics' advancements in gene therapy for sickle cell disease and the promising data from their clinical trials.

Core Insights - ONEOK Inc. (OKE) is benefiting from increased fee-based earnings and capital expenditures aimed at strengthening its position in high-production regions [1][8] - The company is exposed to competitive risks in its pipeline business [1][6] Positive Drivers for OKE - ONEOK is expected to gain from long-term fee-based commitments across its three segments: Natural Gas Gathering and Processing, Natural Gas Liquids, and Natural Gas Pipelines and Refined Products and Crude [2] - More than 88% of its 2024 earnings are fee-based, with over 90% of 2025 revenues anticipated to come from fees [2][8] - The annual growth rate for natural gas liquid volumes from the Rocky Mountain region has exceeded 20%, while natural gas processing volumes have grown at 10% over the past five years [2] Capital Expenditures and Expansion - The company is investing in organic-growth projects to expand its services for crude-oil and natural-gas producers, with capital expenditures expected to be between $2.8 billion and $3.2 billion in 2025 [3] - In February 2025, ONEOK and MPLX LP formed joint ventures to construct a new 400,000 barrel-per-day liquefied petroleum gas export terminal in Texas City, along with a new pipeline connecting to its Mont Belvieu storage facility [4] Headwinds for OKE - ONEOK does not own all the land for its pipelines, which poses risks of incurring higher costs and potential operational impacts if land rights are not renewed [5] - The natural gas and natural gas liquid pipeline industries are highly competitive, with many energy companies forming master limited partnerships to launch pipeline services [6] Stock Performance - Over the past year, OKE shares have increased by 6.1%, compared to the industry's growth of 14.1% [7]

Sanara MedTech Investor Presentation Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the "Company," "Sanara," "we," "our" or "us"). All statements other than statements of historical fact contained herein are forward-looking statements. These statements may be identified by terms such as "aims," "anticipates," "believes," "c ...

Acacia Research (ACTG) FY Conference Summary Company Overview - Acacia Research has transitioned from an intellectual property business to a value-based acquirer of companies, focusing on creating a diversified portfolio of assets [2][3] - The company has a book value of approximately $577 million, translating to about $6 per share, with $340 million in cash and public securities [4] Financial Performance - Acacia generated $222 million in revenue and $61 million in EBITDA, with $40 million of EBITDA related to its former intellectual property business [5] - The company operates with no debt, emphasizing a strong financial position [5] Investment Strategy - The management team, led by the CEO with a private equity background, focuses on acquiring undervalued businesses, particularly in contrarian sectors [6][8] - Acacia aims to improve the operational efficiency and profitability of acquired businesses, emphasizing hands-on management rather than passive ownership [10][11] - The company has seen a significant number of acquisition opportunities, evaluating 350 businesses last year and 280 so far this year, but remains selective [9][50] Recent Acquisitions - Acacia has made strategic acquisitions, including Benchmark Energy and Deflecto, to build a scaled oil and gas platform and diversify its portfolio [15][22] - The acquisition of Benchmark was based on identifying dislocation in the oil and gas market, focusing on cash flow generation rather than traditional valuation metrics [17][19] - Deflecto was acquired as a collection of three unrelated businesses, with plans to streamline operations and enhance value through cost-cutting and management alignment [22][24] Operational Focus - The company emphasizes operational improvements and continuous enhancement of acquired businesses, aiming to generate cash flow and increase margins [11][20] - Acacia's approach includes leveraging existing management expertise and operational partners to drive performance in acquired companies [8][26] Market Position and Future Outlook - Acacia is exploring opportunities in specialty lending and insurance, indicating a strategic focus on markets with limited capital flow [51][52] - The company is cautious about entering new markets, preferring to build around existing positions and leverage its team's expertise [54] - Acacia aims to unlock trapped value in its portfolio, with a long-term vision of growing into a formidable public holding company with multiple large businesses [42][43] Conclusion - Acacia Research is positioned as a value-oriented acquirer with a strong financial foundation and a clear strategy for operational improvement and growth through selective acquisitions [34][55]